To date, only three HDAC inhibitors have been approved by the FDA for the treatments of CTCL (vorinostat (SAHA) and romidepsin (Istodax)) and PTCL (belinostat (Beleodaq) and romidepsin). Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.